## TEM: Tempus AI, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($58.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Canaccord Genui | $80 | $95 | -16% |
| 2025-12-15 | JP Morgan | $80 | $85 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Canaccord Genui | main | Buy |
| 2025-12-15 | JP Morgan | main | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 5.7% (+106.8%)
- BAILLIE GIFFORD & CO: 5.6% (-19.9%)
- Vanguard Group Inc: 5.5% (+22.1%)
- ARK Investment Manag: 4.2% (-3.3%)
- Blackrock Inc.: 3.9% (+62.8%)

### Key Risks

1. High beta (2.66) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.7%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +8.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.49 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.3x). Revenue growth strong at 24% YoY. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.00 |
| 52W Range | $31.36 - $104.32 |
| Short Interest | 13.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.49 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -5.8% to 2.8% (+8.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >3.0% for momentum thesis). MRS_5 at 4.8% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 44. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.83% (CS: 76) | Neutral |
| RSI_14 | 43.6 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 0.884x | Below |
| vs SMA200 | 0.952x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $64.70
- **Stop Loss:** $58.30 (9.9% risk)
- **Target:** $71.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 134
- **Position Value:** $8,669.80
- **Portfolio %:** 8.67%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-24 (Est: $-0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.18 | $-0.11 | +37.3% |
| 2025Q2 | $-0.25 | $-0.22 | +13.0% |
| 2025Q1 | $-0.27 | $-0.24 | +10.2% |
| 2024Q4 | $-0.15 | $-0.18 | -17.5% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*